• 11 May 2026
• Admin
• News Article

Oculis Secures FDA SPA for PIONEER-1: A Step Toward First Neuroprotective Therapy in Optic Neuritis

Oculis Holding AG has reached a key regulatory milestone in its neuro-ophthalmology pipeline. The company announced that the U.S. Food and Drug Administration has granted a Special Protocol Assessment (SPA) agreement for its Phase 3 PIONEER-1 trial.

This trial evaluates Privosegtor in patients with optic neuritis (ON), a condition that can cause permanent vision loss due to optic nerve inflammation.

FDA SPA Agreement: Why It Matters?

An SPA is a formal agreement between a drug developer and the FDA on trial design and endpoints. In this case, the agreement confirms that:

• The PIONEER-1 study design is appropriate for a future NDA submission
• The statistical analysis plan is acceptable
• The trial can serve as a pivotal registrational study if successful

This does not guarantee approval, but it significantly reduces regulatory uncertainty.

What is Privosegtor?

Privosegtor is a first-in-class peptoid small molecule designed to cross both:

• The blood-brain barrier
• The retinal barrier

Its goal is neuroprotection, not just symptom management. Key potential benefits:

• Protects optic nerve cells from irreversible damage
• Improves visual function after acute inflammation
• May extend to other neuro-ophthalmic and neurological diseases

Preclinical and Phase 2 data suggest it preserves retinal ganglion cells and improves functional outcomes.

The PIONEER Program: Path to Registration

Oculis is advancing Privosegtor through the PIONEER program, which includes two registrational trials.

PIONEER-1 Phase 3 Study

• Population: Optic neuritis patients (with and without multiple sclerosis)
• Primary endpoint: ≥15-letter improvement in low-contrast visual acuity at Month 3
• Follow-up: 12 months for safety and tolerability
• Design: Closely aligned with Phase 2 ACUITY trial

Phase 2 ACUITY Results: Proof of Concept

The earlier ACUITY trial showed encouraging outcomes:

• Improved visual function at Month 3
• Sustained benefit through Month 6
• Anatomical and biological evidence of neuroprotection
• No drug-related serious adverse events

Most common side effects:

• Headache
• Acne

These findings contributed to regulatory momentum, including:

• Breakthrough Therapy designation from the U.S. Food and Drug Administration
• PRIME designation from the European Medicines Agency

Clinical Significance: Optic Neuritis and NAION

Optic neuritis is an acute inflammation of the optic nerve, often linked to multiple sclerosis.

Key facts:

• Affects young adults, typically 20–40 years old
• Higher incidence in women
• Can cause irreversible vision loss due to axonal damage
• No approved neuroprotective therapy currently exists

A related condition, non-arteritic anterior ischemic optic neuropathy (NAION), is even more common in older adults and also lacks approved treatments.

Together, these conditions represent a major unmet medical need in ophthalmology.

Market Opportunity and Strategic Positioning

Oculis estimates a potential U.S. market of approximately $7 billion in acute optic neuropathies. Privosegtor aims to address:

• Acute vision loss prevention
• Neuroprotection of optic nerve tissue
• Long-term preservation of visual function

If successful, it could extend beyond ophthalmology into broader neurodegenerative indications.

Expert Perspective

According to clinical collaborators at the Icahn School of Medicine at Mount Sinai, Privosegtor has shown consistent:

• Visual function improvement
• Retinal structural preservation
• Neurobiological protection signals

These findings strengthen its translational potential from lab research to clinical therapy.

SPA in Context: What It Really Changes

The SPA agreement provides:

• Clear regulatory alignment before Phase 3 completion
• Reduced risk of trial design rejection
• Stronger NDA submission foundation

However, key risks remain:

• Clinical efficacy must still be proven in Phase 3
• Safety must hold across larger populations
• Regulatory approval is not guaranteed

Conclusion

With FDA alignment secured, Oculis Holding AG moves closer to potentially delivering the first neuroprotective therapy for optic neuritis.

If successful, Privosegtor could reshape how acute optic nerve injuries are treated—shifting the focus from recovery to true neural protection.